Oxford Biomedica plc announced that Dr. Frank Mathias will officially join the company as Board member on 27th March 2023. His appointment was previously announced on 22nd November 2022. Dr. Frank Mathias joins the company from Rentschler Biopharma SE, where he has been CEO since 2016.

He successfully transformed Rentschler into a leading global, full-service CDMO and transformed the financials of the business including a three-fold increase in revenue, while also improving efficiencies and profitability at an even faster rate. In addition, the company announced two changes to its Board, both of which will also take effect on 27th March 2023. Stuart Henderson will become Vice Chair, a newly created position which replaces the previously combined role of Deputy Chair and Senior Independent Director, the position Stuart has filled since June 2020.

Professor Dame Kay Davies will assume the role of Senior Independent Director, following her appointment as a Non-Executive Director in March 2021.